



Foster consortium

Fight OsteoSarcoma Through European Research


The role of networks in advancing patient care in sarcomas

Emanuela Palmerini, co-Chair of FOSTER consortium MD, PhD, Medical Oncologist, University of Miami, Miami, FL, USA

Nathelie Gaspar, Chair of FOSTER consortium MD PhD, Pediatric oncologist, Gustave Roussy, Paris, France

A unmet need






Osteosarcoma

Rare disease
No survival improvement in 40 years
No new drug in first-line treatment
Few drugs in relapse

No European clinical collaboration since the end of EURAMOS trial in 2012

No European place for discussions between researchers/clinicians

No patient/parent voice



18 y barrier in Phase2

40-50 y barrier in Phase3

A common goal




Over-arching objective

To improve outcome of patients with osteosarcoma, in terms of duration and quality of life of survivors

- to describe the current knowledge,
- to define the unmet needs, the current gaps and missing information
- and to set-up the actions to meet those needs and fill-up these gaps
- to ultimately changes practices and improve survival

Enthusiasm to work together







Open and inclusive Membership

3-4 OCTOBER 2022
GUSTAVE ROUSSY, FRANCE

First FOSTER consortium physical

meeting

Multidisciplinary,

Multigenerational (expert seniors and young investigators),

Multinational (geographic Europe),

Patients and Parents

Medical Oncologist

The network


Radiologist


Radiation Oncologist


Surgeon

Thoracic Surgeon

Orthopedic Surgeon







OSTEOSARCOM4

Structuration of the consortium





- 1 Surgeon

1 Pathologist1 Researcher

- 1 Patient representative

+ 1 Parent representative

Meet FOSTER
Executive
Committee







Structuration of the work



WP1: Biology, Preclinical study, translational research

WP2: Molecular profiling programs, molecularly driven trials, and early drug development

WP3: Relapse trials

WP4: First line trials

WP5: Primary tumour and metastatic local treatments

WP6: Imaging radiomics questions

WP7: Quality of life, functional outcomes and long term effects

WP8: Data sharing and knowledge dissemination

WP9: Predisposition syndroms from biology to treatment

FOSTER patient/parent group

FOSTER young investigator group

Objectives
Milestones
Regular Virtual
meetings


Structuration of the Leadership

Meet the Leaders, co-leaders, secretaries

Elected Leaders

Elected Co-leaders

Volonteer YI Secretary







ter Horst

Wilk Michelsen

Roelof

van Ewijk

Noelle

Cullinan

Elisa

Tirtei

Tlemsani

Pantziarka

Natalia

Fernandez

Elisa

Tirtei

Camille

Tlemsani


To build a common project!




Bring New drugs IN !!!



Bring Biology IN !!!









Mentorship for young investigators



FOSTER minions



YI steering committee



Aims and organisation

- Support the goal of FOSTER and gain expertise / network by driving the work in FOSTER
- Guide new YI in FOSTER / connect YI with experts
- Collaborate with EC to optimize involvement of YI

Need for a project administrative coordination










Esperanza Perez Project manager

FosterConsortium@gustaveroussy.fr

To have an identity

Logo contest Winner





Logo re-designed by **Hanna Narding**





Price: a stay in Paris & a trip to Disneyland Paris for Joanna and her familly offered by Imagine for Margo









Editorial and educational: manuscript dissemination

Reccurrent Osteosarcoma



Cancer Treatment Reviews 120 (2023) 102625

Contents lists available at ScienceDirect

Cancer Treatment Reviews

journal homepage: www.elsevier.com/locate/ctrv



Systematic or Meta-analysis Studies

A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?



Roelof van Ewijk^a, Morgane Cleirec^b, Nikolas Herold^c, Marie-Cécile le Deley^{d,e}, Natasha van Eijkelenburg^a, Pascaline Boudou-Rouquette^f, Séverine Risbourg^d, Sandra J. Strauss^g, Emanuela Palmerini^h, Kjetil Boyeⁱ, Leo Kager^{j,k}, Stefanie Hecker-Nolting^l, Antonin Marchais^{m,n}, Nathalie Gaspar^{m,n,c}, On behalf of the FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 3 on recurrent/refractory osteosarcoma trials

Van Ewijk R et al, Can Tre Rev 2023

Prognostic Factor Newly DiagnosedOsteosarcoma

"Prognostic factors in newly diagnosed high-grade osteosarcoma - a systematic review" by Tirtei, Elisa; Michelsen, Sascha Wilk; Haveman, Lianne; Meazza, Cristina; Oliveira, Joana F.; Rasool, Ayesha; Palmerini, Emanuela; Wilson, William; GASPAR, NATHALIE; Strauss, Sandra; Papakonstantinou, Andri; Baecklund, Fredrik, has been successfully submitted online and is presently being given full consideration for publication in Cancer Medicine.

Tirtei E et al, CAM 2025

Publications

THE ROLE OF NETWORK

Guidelines and Collaborations with other Societies

Position Papers

Contents lists available at ScienceDirect




EJC Paediatric Oncology

journal homepage: www.journals.elsevier.com/ejc-paediatric-oncology



Review







Van Ewijk R et al, E J of Ped onc 2023

CLINICAL CANCER RESEARCH | PERSPECTIVE

Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement

Darrell Green¹, Roelof van Ewijk², Elisa Tirtei^{3,4}, Dimosthenis Andreou⁵, Fredrik Baecklund⁶, Daniel Baumhoer⁷, Stefan S. Bielack⁸, Rajesh Botchu⁹, Kjetil Boye¹⁰, Bernadette Brennan¹¹, Daniel Baumhoer', Stefan S. Bielack', Rajesh Botchu', Kjetil Boye'', Bernadette Brennan'', Michael Capra'², Lucia Cottone¹³, Uta Dirksen¹⁴, Franca Fagioli^{3,4}, Natalia Fernandez¹⁵, Adrienne M. Flanagan^{13,16}, Marco Gambarotti¹⁷, Nathalie Gaspar^{18,19}, Hans Gelderblom²⁰, Craig Gerrand²¹, Anne Gomez-Mascard^{22,23}, Jendrik Hardes²⁴, Stefanie Hecker-Nolting⁸, Edita Kabickova²⁵, Leo Kager^{26,27}, Jukka Kanerva²⁸, Lennart A. Kester², Marieke L. Kuijigr^{29,30,31}, Valérie Laurence³², Cyril Lervat³³, Antonin Marchais¹⁸, Perrine Marec-Berard³⁴, Cristina Mendes³⁵, Johannes H.M. Merks^{2,36}, Benjamin Ory³⁷, Emanuela Palmerini³⁸, Pan Pantziarka^{15,39,40}, Evgenia Papakonstantinou⁴¹, Sophie Piperno-Neumann³³, Anna Raciborska⁴², Elizabeth A. Roundhill⁴³, Vilma Rutkauskaite⁴⁴, Akmal Safwat⁴⁵, Katia Scotlandi⁴⁶, Eric L. Staals⁴⁷, Ended Strausr⁴⁸, Didire Surdar⁴⁹, Cum M. Sur⁵⁰, Maria Deniziqua Deniziqua Tabana⁵¹ Sandra J. Strauss⁴⁸, Didier Surdez⁴⁹, Gwen M.L. Sys⁵⁰, Marie-Dominique Tabone⁵¹, Maud Toulmonde⁵², Claudia Valverde⁵³, Michiel A.J. van de Sande⁵⁴, Klaus Wörtler⁵⁵, Quentin Campbell-Hewson^{56,1}, Martin G. McCabe^{57,58}, and Michaela Nathrath^{59,60}



Quality of Life



REVIEW ARTICLE

The landscape of Functional Outcome Measures Used in Patients with Bone Sarcoma of the Lower Extremity or Pelvis: A Systematic Review

Leonie G. Tigelaar, Kiki J. Blom, Willem P. Bekkering, Jos A. M. Bramer, Hendrik W. B. Schreuder, Sherron Furtado, Craig H. Gerrand, Emanuela Palmerini, Nathalie Gaspar, Sandra J. Strauss, Michiel A. J. Van de Sande, Johannes H. M. Merks, Lianne M. Haveman FOSTER Consortium and the EuroEwing Consortium

Tigelaar LG et al, J Surg Onc 2024

Research Article

Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review

Ana Sebio 0, 1 Claire Berger 0, 2 Marie-Dominique Tabone 0, 3 Natalia Fernandez 0, 4 Faustine Tardy 0, 2 Martha Grootenhuis 0,5 Emanuela Palmerini 0,67,8 Nathalie Gaspar 0,9 Michiel van de Sande 0,5 Lianne M. Haveman 0,5 and on behalf of the FOSTER Consortium1

Department of Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain ²Department of Pediatric Hematology and Oncology Unit, CHU Saint-Etienne, Saint-Etienne, France ³Department of Pediatric Onco-Hematology, Armand Trousseau Hospital, Paris, France ⁴Departamento de Turismo y Hosteleria, University Escuela de Turismo y Hostelería, Barcelona, Spain ⁵Department of Solid Tumors, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands ⁶Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA ⁸Miller School of Medicine, University of Miami, Miami, Florida, USA

Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif, France

Sebio A et al, E J of Can Care 2025

Randomisation


Clinical Trials and Grant support











To open in Dec 2024 - Jan 2025

A constant reminder on why we started all that



Strong Patient and Parent involvement





- Involved in each FOSTER consortium
 WP
- Contribution to trial design discussions in first line and in relapse, including the choice of drug and the issue of placebo-control or not
- Feedback on the funding/trial applications that FOSTER members have been involved in, including the design of patient and public involvement (PPI) activities, discussions of dissemination of results
















FOSTER-EC members

Physical interactions

...or the **OPPORTUNITY?**









THANK YOU



https://fosterconsortium.org/

FosterConsortium@gustaveroussy.fr nathalie.gaspar@gustaveroussy.fr

4th FOSTER meeting Warsav, 26-27 of September 2025

ACKNOWLEDGMENTS







Patient and Parent associations













Accelerate Together Rare Cancer Treatment







FOSTER-CaboS part-2





2023















SARKOME DEUTSCHE SARKOM STIFTUNG















